Implications for life sciences New capabilities to adapt across the value chain TODAY FUTURE R&D / Portfolio • Focus on oncology and specialty Refocus portfolio strategy on high-unmet need areas Strategy • On-site complex protocol studies Innovative use of RW evidence Tech-enabled execution Safety • Traditional PV requirements Long-termfollow-up COVID-19 patients Evidence on COVID-19 impact Supply and • Dependent on foreign API Considerdomestic / collaborative manufacturing to prevent Manufacturing • Consistent and frequent distribution / wholesale any supply issues or policy changes Pricing and • Price benchmarks Plan for new evidence requirements Market Access • External technology review Accelerated focus on value demonstration Patient Support • Disease state and treatment education focus Enhance support for patients within new care sites • On-site specialist referrals Strengthen pathways and guidelines to empower patients in and Engagement • Hospital driven treatment and care care seeking behaviors Remote monitoring and tele-health continuation • Share of voice based customer engagement Local precision and coordination GTM Model • Coverage and frequency models (F2F focus) Call-center based remote engagement • Key account management Scientific / clinically focused field-team IQVIA Global Executive Briefing: COVID-19 June 2020; Copyright 2020 IQVIA. 24